Stefan Scheidler, MD
Adult Medicine · Kennett, MONPI 1669525275
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 323 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,382 and has fallen 96.6% since, to $47 in 2024.
Across 323 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$789
- AstraZeneca$475
- Boehringer Ingelheim$471
- Amarin Pharma, Inc.$364
- GSK$352
- Lilly USA, LLC$324
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,61098%
- Education$932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $789 |
| AstraZeneca | 28 | $475 |
| Boehringer Ingelheim | 30 | $471 |
| Amarin Pharma, Inc. | 29 | $364 |
| GSK | 26 | $352 |
| Lilly USA, LLC | 21 | $324 |
| Johnson & Johnson | 22 | $296 |
| Merck | 18 | $260 |
| Pfizer | 17 | $188 |
| Astellas Pharma US Inc | 8 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $136 |
| E.r. Squibb & Sons, L.L.C. | 8 | $118 |
| Sunovion Pharmaceuticals Inc. | 10 | $106 |
| Sanofi-aventis U.S. LLC | 6 | $95 |
| Otsuka America Pharmaceutical, Inc. | 6 | $86 |
| Teva Pharmaceuticals USA, Inc. | 3 | $74 |
| Amgen | 4 | $61 |
| AbbVie | 3 | $43 |
| Eisai Inc. | 3 | $41 |
| Grifols USA, LLC | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 1 | $27 |
| IBSA Pharma Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Corium, LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Bayer | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Abbott | 1 | $12 |
How this compares
Too few adult medicine providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 600 | $190,134 |
| FarxigaDapagliflozin Propanediol | 241 | $108,106 |
| JanuviaSitagliptin Phosphate | 258 | $93,486 |
| TrulicityDulaglutide | 96 | $90,001 |
| JardianceEmpagliflozin | 215 | $84,173 |
| RybelsusSemaglutide | 73 | $71,792 |
| OzempicSemaglutide | 70 | $67,959 |
| Invega SustennaPaliperidone Palmitate | 20 | $65,903 |
| VascepaIcosapent Ethyl | 176 | $48,361 |
| XareltoRivaroxaban | 60 | $45,979 |
| MyrbetriqMirabegron | 180 | $42,116 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $38,044 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $31,240 |
| Tresiba Flextouch U-100Insulin Degludec | 69 | $30,413 |
| LinzessLinaclotide | 56 | $30,044 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $188 | $190,134600 claims |
| Novo NordiskRybelsus, Ozempic | $789 | $139,751143 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $475 | $121,772258 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $324 | $116,436113 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $471 | $113,304277 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $296 | $111,88180 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $352 | $100,300218 claims |
| MerckJanuvia | $260 | $93,486258 claims |
| AbbVieLinzess, Creon, Synthroid, Namzaric, Lumigan | $43 | $89,651718 claims |
| Astellas Pharma US IncMyrbetriq | $185 | $42,116180 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $86 | $24,92630 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $136 | $14,86861 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Missourion file to place this against a meaningful peer group, so we don't.
Other adult medicine in Kennett
- Barbara ObrienEllisville$1K
- Shelly HouseIndependence$959
- Azalie ArmknechtBranson$866
- Lauren RileyBlue Springs$815
- Michael ColeSaint Louis$317
- Madhuri SubbaiahSaint Louis$296
- Samuel EvansWest Plains$248
- David RyanTrenton$239
- Mahrukh KhanSt. Louis$238
- Eduard RasputkovKirksville$214
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.